<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594839</url>
  </required_header>
  <id_info>
    <org_study_id>ILD-01</org_study_id>
    <nct_id>NCT02594839</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease</brief_title>
  <official_title>A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the safety and the efficacy of the addition of intravenous&#xD;
      transplantation of donor bone marrow mesenchymal stem cells in patients with idiopathic&#xD;
      interstitial pneumonia or connective tissue disease associated with interstitial lung&#xD;
      disease, which have actively progressing disease with rapid loss of pulmonary function on the&#xD;
      background of routine treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite significant progress in the treatment of interstitial lung disease, achieved thanks&#xD;
      to new drugs, such as pirfenidone and nintedanib, there are many patients for whom these&#xD;
      drugs are not available or poorly tolerated. In addition significant evidence of their&#xD;
      effectiveness and safety is valid only for idiopathic pulmonary fibrosis. The transplantation&#xD;
      of allogeneic stem cells is a promising direction in the modern medicine with the proven&#xD;
      safety for different diseases. But the effectiveness of this therapy is still under research.&#xD;
      We believe that in most severe cases of a rapidly progressive interstitial lung disease the&#xD;
      transplantation of mesenchymal stem cells may be an effective technology due to their&#xD;
      immunomodulatory properties.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number of serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>registration of adverse events related to infusion and 12 months follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLCO changes from baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of the diffusing lung capacity at 3, 6, 9, 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC changes from baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of spirometry at 3, 6, 9, 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise capacity changes</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of 6MWD at 3, 6, 9, 12 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Idiopathic Interstitial Pneumonia</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone marrow mesenchymal stem cells</intervention_name>
    <description>Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline</description>
    <arm_group_label>MSCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion of 400 mL saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients 20-80 years old&#xD;
&#xD;
          -  Diagnosis of idiopathic interstitial pneumonia or secondary to connective tissue&#xD;
             diseases interstitial lung disease, based on:&#xD;
&#xD;
               -  Clinical symptoms &gt; 12 months duration,&#xD;
&#xD;
               -  Histologically diagnosed or diagnostic chest HRCT features of interstitial&#xD;
                  pneumonia&#xD;
&#xD;
          -  Forced Vital Capacity (FVC) ≥ 40% predicted and Diffusing Lung Capacity (DLCO) ≥20%&#xD;
&#xD;
          -  Loss more than 10% of FVC (L) and DLCO during the last 12 months&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an interstitial lung disease other than idiopathic interstitial pneumonia&#xD;
             or connective tissue disease associated with interstitial lung disease (sarcoidosis,&#xD;
             pulmonary alveolar proteinosis, lymphangioleiomyomatosis, pulmonary amyloidosis,&#xD;
             exposure-related lung disease etc)&#xD;
&#xD;
          -  Obstructive lung disease: FEV1/FVC &lt; 0.70&#xD;
&#xD;
          -  Clinically significant medical condition, in the opinion of the investigator, may&#xD;
             compromise the results of the study&#xD;
&#xD;
          -  Evidence of active infection within 4 week prior to enrollment&#xD;
&#xD;
          -  History of malignancy &lt; 5 years prior to enrollment&#xD;
&#xD;
          -  Unable to cooperate with any study procedures&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Treatment with antiinflammatory or antifibrotic drugs including oral steroids,&#xD;
             cytostatic drugs, pirfenidone, D penicillamine, colchicine, tumor necrosis factor α&#xD;
             blockers, imatinib, interferon γ, monoclonal antibodies &lt; 6 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Active listing for transplant of any organ.&#xD;
&#xD;
          -  Known history of alcohol abuse within 1 year prior to enrollment&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Federal Research Clinical Center FMBA of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 1, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interstitial lung disease</keyword>
  <keyword>idiopathic interstitial pneumonia</keyword>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Hamman-Rich Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

